20 Feb 2025
Date 20 Feb 2025 (Thursday)
Time 1:00 pm – 2:00 pm
Topics & Speakers Presented by
Dr Tony Tan
Chairman Maternal Fetal Medicine Section, College of O&G Singapore and Consultant Obstetrician and Gynaecologist Mount Alvenia Hospital
Panellists
A/Prof Tan Lay Kok
President College of O&G Singapore; Head and Senior Consultant of Maternal Fetal Medicine Department, KK Women’s and Children’s Hospital
Dr Muniswaran Ganeshan
President OGSM; Maternal Fetal Medicine Consultant and Obstetrician & Gynaecologist, Pantai Hospital Kuala Lumpur
Prof Arijit Biswas
Senior Consultant, Division of Maternal Fetal Medicine, Department of Obstetrics and Gynaecology, National University Hospital
A/Prof Yung Chee Fu
Senior Consultant, Infectious Disease Service, KK Women’s and Children’s Hospital
Dr Leong Hoe Nam
Medical Director, Senior Consultant, Infectious Diseases Physician, Rophi Clinic
Prof David Baud
Head, Obstetric Service, Lausanne University Hospital
The 5 articles are as follows:
1. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
2. RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes
3. Longer interval between maternal RSV vaccination and birth increases placental transfer efficiency
4. Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial
5. Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine
A new RSV vaccine has recently been approved for maternal vaccination by HSA.
The following issues will be discussed:
1. How serious and how common is RSV infection in infants < 6 months old?
2. Premature births have been associated with a 1-2% increase in preterm birth when RSV vaccination is given at 24-34 weeks. Is this a random finding? What other mechanisms could cause this?
3. RCTs were done for maternal RSV vaccination at 24-34 weeks, yet one maternal RSV vaccine was licensed for use at 32-36 weeks without a similar RCT showing its efficacy during this gestation. Could the efficacy at 32-36 weeks be less than that when given at 24-34 weeks? Do we have long term follow-up of babies born after maternal RSV vaccination?
4. Should COGS / MOH recommend that maternal RSV vaccination be offered to all pregnant women at 32-36 weeks?
5. UK and Australian recommend that all pregnant women be offered maternal RSV vaccination from 28 weeks onwards. What are your views on this approach?
6. Nirsevimab (RSV monoclonal antibody) can be given to infants < 8 months old to prevent infant RSV infection. Is this a better approach to prevent infant RSV infection? Do OGs offering maternal RSV vaccination have to discuss this alternative approach with the patients too?
Registration is free! Please register here by 18 February 2025.
*1 CME point accredidated
